These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32277760)

  • 21. Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement.
    Hamad N; Gottlieb D; Ritchie D; Kennedy G; Watson AM; Greenwood M; Doocey R; Perera T; Spencer A; Wong E; O'Brien T; Shaw P; Conyers R; Cole T; Milliken S; Bardy P; Larsen S; Lai H; Butler A; Fraser C; Bajel A; Butler J; Kerridge I; Purtill D
    Intern Med J; 2020 Jun; 50(6):774-775. PubMed ID: 32537929
    [No Abstract]   [Full Text] [Related]  

  • 22. COVID-19 and thrombosis: Prophylaxis and management.
    Canoğlu K; Şaylan B; Çalışkan T
    Tuberk Toraks; 2021 Jun; 69(2):269-278. PubMed ID: 34256519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. South African guidelines on venous thromboembolism.
    Webb MJ; Mlombe Y; Louw VJ
    S Afr Med J; 2009 Sep; 99(9):614; author reply 614. PubMed ID: 20073278
    [No Abstract]   [Full Text] [Related]  

  • 24. Awareness and Prophylaxis of Venous Thromboembolism in Patients with COVID-19: A National Cross-Sectional Survey in Epidemic Era.
    Zhang Z; Xi L; Zhang S; Zhang Y; Pang W; Wang Y; Li C; Zhai Z; Wang C
    J Atheroscler Thromb; 2020 Oct; 27(10):1123-1137. PubMed ID: 32863290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
    Marietta M; Tripodi A
    Blood Transfus; 2020 May; 18(3):239-240. PubMed ID: 32453693
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk Benefit Analysis in Reference to use of LMWH in COVID-19.
    Samajdar SS; Sam PA; Moitra S; Ray Y; Pal J; Joshi SR; Tripathi SK
    J Assoc Physicians India; 2020 Sep; 68(9):52-61. PubMed ID: 32798346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controversial issues in thromboprophylaxis with low-molecular weight heparins in palliative care.
    Tassinari D; Santelmo C; Scarpi E; Tombesi P; Sartori S
    J Pain Symptom Manage; 2008 Aug; 36(2):e3-4. PubMed ID: 18655952
    [No Abstract]   [Full Text] [Related]  

  • 28. Laboratory haemostasis monitoring in COVID-19.
    Thachil J; Tang N; Gando S; Falanga A; Levi M; Clark C; Iba T
    J Thromb Haemost; 2020 Aug; 18(8):2058-2060. PubMed ID: 32324960
    [No Abstract]   [Full Text] [Related]  

  • 29. Thromboprophylaxis for medical inpatients with coronavirus disease 2019.
    Dalager-Pedersen M; Bodilsen J
    Clin Microbiol Infect; 2020 Sep; 26(9):1125-1126. PubMed ID: 32454190
    [No Abstract]   [Full Text] [Related]  

  • 30. The Role of Low Molecular Weight Heparins for Venous Thromboembolism Prevention in Medical Patients-What Is New in 2019?
    Haas S
    Hamostaseologie; 2019 Feb; 39(1):62-66. PubMed ID: 30620990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin for thromboprophylaxis.
    Camporese G; Bernardi E
    Curr Opin Pulm Med; 2009 Sep; 15(5):443-54. PubMed ID: 19593139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AMB Guidelines: COVID -19.
    Ferreira LL; Sampaio DL; Chagas ACP; Guimarães HP; Hajjar LA; Lobo SMA; Abdo CHN; Bonamigo Filho JL; Bacha HA; Moura RF; Bernardo WM
    Rev Assoc Med Bras (1992); 2020; 66Suppl 2(Suppl 2):17-21. PubMed ID: 32965349
    [No Abstract]   [Full Text] [Related]  

  • 33. Venous thromboembolism and COVID-19: a case report and review of the literature.
    Bhatt H; Singh S
    J Med Case Rep; 2020 Oct; 14(1):188. PubMed ID: 33054805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risks and benefits of low molecular-weight heparin and target-specific oral anticoagulant use for thromboprophylaxis in medically ill patients.
    Hale G; Brenner M
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):311-22. PubMed ID: 25957095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ; Turpie AG
    Circulation; 2005 Jan; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin.
    Paciaroni M; Ageno W; Agnelli G
    Thromb Haemost; 2008 May; 99(5):978-80. PubMed ID: 18449438
    [No Abstract]   [Full Text] [Related]  

  • 37. Narrowing in on the True Rate of Venous Thromboembolism in Hospitalized Patients With COVID-19 Disease.
    Siegal DM; Gross PL
    Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):1958-1960. PubMed ID: 32762455
    [No Abstract]   [Full Text] [Related]  

  • 38. European guidelines on perioperative venous thromboembolism prophylaxis: Neurosurgery.
    Faraoni D; Comes RF; Geerts W; Wiles MD;
    Eur J Anaesthesiol; 2018 Feb; 35(2):90-95. PubMed ID: 29112542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European guidelines on perioperative venous thromboembolism prophylaxis: Surgery in the elderly.
    Kozek-Langenecker S; Fenger-Eriksen C; Thienpont E; Barauskas G;
    Eur J Anaesthesiol; 2018 Feb; 35(2):116-122. PubMed ID: 28901992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
    Rasmussen MS; Jørgensen LN; Wille-Jørgensen P
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004318. PubMed ID: 19160234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.